Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 1/20 | 0.40 |
| ▸ | MCHR1 | Q99705 | 11/20 | 0.36 |
| ▸ | MBOAT4 | Q96T53 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | APLNR | P35414 | 1/20 | 0.33 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30047078 | 1.00 | GBA1 (0.40) | GBA1MCHR1MBOAT4KDM4EALDH1A1 | |
| SCHEMBL4056065 | 0.83 | GBA1 (0.38) | GBA1MCHR1MBOAT4KDM4EALDH1A1 | |
| SCHEMBL12661548 | 0.81 | SYK (0.39) | KDM4EALDH1A1 | |
| SCHEMBL506719 | 0.79 | HTR2A (0.39) | MCHR1MBOAT4APLNR | |
| SCHEMBL15986833 | 0.79 | CYP1A2 (0.32) | — | |
| SCHEMBL1001775 | 0.79 | PTGS1 (0.37) | MCHR1MBOAT4KDM4EALDH1A1GRM2 | |
| SCHEMBL23977388 | 0.79 | ALDH1A1 (0.40) | KDM4EALDH1A1 | |
| SCHEMBL18326358 | 0.78 | APLNR (0.40) | MCHR1MBOAT4APLNR | |
| SCHEMBL19539397 | 0.78 | MMP2 (0.35) | KDM4EALDH1A1 | |
| SCHEMBL16180689 | 0.77 | GBA1 (0.41) | GBA1MBOAT4KDM4EALDH1A1GRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240246937-A1 | IL4I1 INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2024-07-25 | — | — | US | disclosed |
| US-12037324-B2 | Biarylmethyl heterocycles | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-07-16 | — | — | US | disclosed |
| US-12037324-B2 | Biarylmethyl heterocycles | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-07-16 | — | — | US | disclosed |
| US-12037324-B2 | Biarylmethyl heterocycles | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-07-16 | — | — | US | disclosed |
| EP-3478672-B1 | BIARYLMETHYL HETEROCYCLES | UNIV MONTREAL (CA) | 2024-04-10 | — | — | EP | disclosed |
| EP-4329889-A1 | IL4I1 INHIBITORS AND METHODS OF USE | Merck Sharp & Dohme LLC (US) | 2024-03-06 | — | — | EP | disclosed |
| US-11814364-B2 | Pyridine N-oxide derivatives useful as factor XIa inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-14 | — | — | US | disclosed |
| EP-3555080-B1 | OXAZINE DERIVATIVES AS BETA-SECRETASE INHIBITORS AND METHODS OF USE | AMGEN INC (US) | 2023-09-20 | — | — | EP | disclosed |
| US-20230091768-A1 | PYRIDINE N-OXIDE DERIVATIVES USEFUL AS FACTOR XIA INHIBITORS | JANSSEN RESEARCH & DEVELOPMENT, LLC | 2023-03-23 | — | — | US | disclosed |
| US-20230045357-A1 | BIARYLMETHYL HETEROCYCLES | Université de Montréal (CA) | 2023-02-09 | — | — | US | disclosed |
| US-20090124578-A1 | SPIRO-OXAZOLIDINONE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS | ASTRAZENECA AB (SE) | 2009-05-14 | — | — | US | disclosed |
| US-20090124578-A1 | SPIRO-OXAZOLIDINONE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS | ASTRAZENECA AB (SE) | 2009-05-14 | — | — | US | disclosed |
| US-20090124578-A1 | SPIRO-OXAZOLIDINONE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS | ASTRAZENECA AB (SE) | 2009-05-14 | — | — | US | disclosed |
| US-7485722-B2 | Spiro-oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators | ASTRAZENECA AB (SE) | 2009-02-03 | — | — | US | disclosed |
| US-7485722-B2 | Spiro-oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators | ASTRAZENECA AB (SE) | 2009-02-03 | — | — | US | disclosed |
| US-7485722-B2 | Spiro-oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators | ASTRAZENECA AB (SE) | 2009-02-03 | — | — | US | disclosed |
| US-20080125431-A1 | Spiro-oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators | ASTRAZENECA (SE) | 2008-05-29 | — | — | US | disclosed |
| US-20080125431-A1 | Spiro-oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators | ASTRAZENECA (SE) | 2008-05-29 | — | — | US | disclosed |
| US-20080125431-A1 | Spiro-oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators | ASTRAZENECA (SE) | 2008-05-29 | — | — | US | disclosed |
| WO-2008032191-A2 | SPIRO-OXAZOLIDINONE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS | ASTRAZENECA AB (US) | 2008-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124578-A1 | SPIRO-OXAZOLIDINONE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS | GRM1, GRIN1, GRM2 | GBA1 2434/4885MCHR1 557/4885MBOAT4 1101/4885 |
| US-20230091768-A1 | PYRIDINE N-OXIDE DERIVATIVES USEFUL AS FACTOR XIA INHIBITORS | F11, F2, KLKB1 | GBA1 3204/4885MCHR1 4642/4885MBOAT4 4650/4885 |
| US-20080125431-A1 | Spiro-oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators | GRM1, GRIN1, GRM2 | GBA1 2434/4885MCHR1 557/4885MBOAT4 1101/4885 |
| US-12037324-B2 | Biarylmethyl heterocycles | ARRB1, ADRB2, ADRB1 | GBA1 3463/4885MCHR1 201/4885MBOAT4 2619/4885 |
| US-11814364-B2 | Pyridine N-oxide derivatives useful as factor XIa inhibitors | F11, F2, KLKB1 | GBA1 3204/4885MCHR1 4642/4885MBOAT4 4650/4885 |
| US-20240246937-A1 | IL4I1 INHIBITORS AND METHODS OF USE | IL4I1, IL4, IL2 | GBA1 2959/4885MCHR1 2416/4885MBOAT4 4078/4885 |
| US-20230045357-A1 | BIARYLMETHYL HETEROCYCLES | ARRB1, ADRB2, ADRB1 | GBA1 3463/4885MCHR1 201/4885MBOAT4 2619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.